Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
You may also be interested in...
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Biotie Therapies gets $20 million as UCB exercises its option on the investigational Parkinson's disease therapy tozadenant and asks the Finnish biotech to continue its clinical development of the product into Phase III.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.